- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01106053
Pramipexole for Binge Eating Disorder
May 3, 2013 updated by: Kristine Steffen, Neuropsychiatric Research Institute, Fargo, North Dakota
An Exploration of the Effects of the Dopamine Agonist Pramipexole on Binge Antecedants, Binge Frequency, and Weight in Binge Eating Disorder
This study is being conducted to evaluate the effects that the drug pramipexole has on mood, food craving, and other behaviors that may be related to binge eating disorder.
Study Overview
Study Type
Interventional
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female
- Age 18-50 years
- Women of child-bearing potential and males must agree to practice an accepted method of birth control. All women must have a negative pregnancy test at baseline.
- Good general health as demonstrated by history and physical examination.
- Body mass index of 30 kg/m2 or higher at the screening visit.
- Meet criteria for binge eating disorder as assessed through the SCID-1 and EDE.
Exclusion Criteria:
- Subjects with any unstable medical condition, or any current or past medical condition which in the opinion of the study physician and/or the principal investigator may increase the risks associated with pramipexole and study participation. Medical appropriateness will be determined through history and physical exam.
- Subjects with any current Axis I psychiatric diagnosis as determined through the Structured Clinical Interview for DSM-IV for Axis I disorders (SCID-1) interview (aside from BED).
- Subjects with a Hamilton Depression Rating Scale score greater than or equal to 12 at the screening visit.
- Subjects who report any history of hallucinations or delusions.
- Participants taking an antidepressant or other regularly used psychotropic medication which may confound the study results
- Subjects with any current or history of an impulse control spectrum disorder, other than binge eating disorder,(such as pathological gambling, compulsive shopping, etc.) at screening as determined by the Structured Clinical Interview for DSM-IV Impulse Control Module.
- Subjects with any history of suicide attempts or current suicidal ideations.
- Subjects that have used tobacco products on a routine basis within the past six months.
- Subjects enrolled in any formal treatment programs or research protocols for binge eating disorder at present, or within the past 30 days.
- Subjects routinely taking any medication known to produce weight change (ex. olanzapine, amitriptyline, steroid medications, etc., other than oral contraceptives, stable thyroid replacement drugs, etc.), or medications with drug-drug interactions with pramipexole.
- Subjects who are currently breast-feeding.
- Subjects who have participated in an investigational drug trial in the past 30 days.
- Subjects who meet DSM IV-TR criteria for alcohol or drug abuse in the past year.
- Subjects with an allergy to pramipexole or tablet constituents.
- Subjects with hepatic dysfunction as determined through a hepatic panel obtained at the screening visit.
- Subjects with an elevated blood pressure or pulse at screening (140/90 mmHg or above or pulse of greater than 100 beats/minute after being seated and stationary for at least five minutes, or as determined at the discretion of the study physician and/or principal investigator) or history of serious cardiac events (myocardial infarction, arrhythmia, stroke, etc).
- Subjects with a history of renal dysfunction or with a creatinine clearance of less than 60 ml/min based upon a serum creatinine obtained during screening and as calculated with the Cockroft and Gault equation.
- Subjects with a positive urine drug screen.
- Any participant with Parkinson's disease or symptoms suggestive of probable Parkinson's disease.
- Subjects who have an Epworth Sleep Scale (ESS) score of >7 at screening. ESS scores > 7 have been associated with an increased risk of sleep attacks (Plowman et al., 2005).
- Any participant who demonstrates clinically significant orthostatic blood pressure changes or is symptomatic during the screening visit, as defined under "orthostatic blood pressure monitoring."
- History of bariatric surgery.
- Participants who report a history of obstructive sleep apnea, excessive fatigue, or any sleep disorder which in the opinion of the principal investigator or study medical personnel would increase the participant's risk of experiencing excessive somnolence with pramipexole.
- Participant has had a change in medication regimen in the last month (dose, starting a new medication, or stopping a medication).
- Participant is employed by, or has an immediate family member employed by NRI.
- Participant has participated in a formal weight loss program in the last month (e.g. Weight Watchers, Jenny Craig, etc.)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Pramipexole
Open-label trial of pramipexole.
|
Pramipexole tablet titrated up to a maximum dosage of 0.5 mg three times daily (1.5 mg/day).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Frequency of binge eating
Time Frame: Baseline followed by weekly during the seven week protocol
|
Baseline followed by weekly during the seven week protocol
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Body weight
Time Frame: Baseline followed by weekly during the seven week protocol
|
Baseline followed by weekly during the seven week protocol
|
Frequency and extent of craving for food using validated instruments
Time Frame: Baseline followed by weekly during the seven week protocol
|
Baseline followed by weekly during the seven week protocol
|
Assessment of mood ratings using a validated instrument
Time Frame: Baseline followed by weekly during the seven week protocol
|
Baseline followed by weekly during the seven week protocol
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Kristine J Steffen, PharmD, PhD, Neuropsychiatric Research Institute, Fargo, ND
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2010
Primary Completion (ACTUAL)
July 1, 2011
Study Registration Dates
First Submitted
April 15, 2010
First Submitted That Met QC Criteria
April 15, 2010
First Posted (ESTIMATE)
April 19, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
May 6, 2013
Last Update Submitted That Met QC Criteria
May 3, 2013
Last Verified
May 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Signs and Symptoms, Digestive
- Hyperphagia
- Disease
- Bulimia
- Feeding and Eating Disorders
- Binge-Eating Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Protective Agents
- Dopamine Agonists
- Dopamine Agents
- Antioxidants
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Pramipexole
Other Study ID Numbers
- NEDA-Pramipexole
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Binge Eating Disorder
-
University of North Carolina, Chapel HillThe Hilda & Preston Davis Foundation; Global Foundation for Eating DisordersCompletedEating Disorder | Binge-eating DisorderUnited States
-
ShireCompleted
-
Lindner Center of HOPEUniversity of CincinnatiCompleted
-
Sao Jose do Rio Preto Medical SchoolFundação de Amparo à Pesquisa do Estado de São PauloCompletedBinge-Eating Disorder | Eating Disorders | Eating Behavior | Eating Disorder | Binge Eating Disorder Associated With ObesityBrazil
-
Nova Scotia Health AuthorityCompletedBinge-Eating Disorder | Eating DisorderCanada
-
BioprojetRecruiting
-
Lindner Center of HOPEJazz PharmaceuticalsRecruiting
-
Idorsia Pharmaceuticals Ltd.Completed
-
University of ChicagoTakedaCompleted
Clinical Trials on Pramipexole
-
Boehringer IngelheimTerminatedTourette SyndromeUnited States, Germany
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedParkinson DiseaseFrance, Germany, Netherlands
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedParkinson Disease